TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06047379: Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Sponsor: Neonc Technologies, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 134 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$11,152,680

Rescue Site Savings

+$7,343,490

Unlock Full NCT06047379 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06047379 Rescue Dossier →